The problem of compliance to cholesterol altering therapy.
about
Interventions to improve adherence to lipid lowering medicationInterventions to improve adherence to lipid lowering medicationPopulation impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart diseaseOptimal lipid modification: the rationale for combination therapyIntegration of biosensors and drug delivery technologies for early detection and chronic management of illnessAssessment of commonly available education materials in heart failure clinicsNoncompliance in the use of cardiovascular medications in the Medicare Part D populationDoes the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort studyAntithrombotic Utilization Trends after Noncardioembolic Ischemic Stroke or TIA in the Setting of Large Antithrombotic Trials (2002-2009).Promoting knowledge of statins in patients with low health literacy using an audio booklet.Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up studyAssociation between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease.Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy.Does medication adherence following a copayment increase differ by disease burden?Effects of an online personal health record on medication accuracy and safety: a cluster-randomized trial.Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up.Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatinAdherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome.Association of Medicare Part D medication out-of-pocket costs with utilization of statin medicationsEffects of an enhanced secondary prevention program for patients with heart disease: a prospective randomized trial.Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.Diabetes information technology: designing informatics systems to catalyze change in clinical careImpact of drugs counselling by an undergraduate pharmacist on cardiac surgical patient's compliance to medicines.Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications.Medication Nonadherence: The Role of Cost, Community, and Individual Factors.Keeping an eye on cardiovascular risk. A practical, case-study approach to assessment in office practice.Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients.Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy.Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study.Effects of cerivastatin withdrawal on statin persistence.Caring for themselves: facilitators and barriers to women home care workers who are chronically ill following their care plan.Electronic monitoring of compliance to lipid-lowering therapy in clinical practice.Disease-specific health literacy, disease knowledge, and adherence behavior among patients with type 2 diabetes in Taiwan
P2860
Q24236817-2B4F6479-EF0F-4A83-9279-3F3071C28365Q24245739-E1D76531-A2DE-4EB1-BF6A-A0C045659C30Q24682494-906631D5-1DCA-418F-9361-B66E676EB7A8Q28219266-9B2463A4-B67D-4759-8F63-61F618543DD6Q30451853-C3E3EBBC-FC20-45EA-A301-403851B1E026Q33557358-C169C942-82A7-4EB9-8A00-6F4D19D3E41EQ33567812-9DC4D316-DBAA-4CFC-A662-D7A36B09703DQ33582496-D1B8BDB2-283B-4DE3-B9DF-421A6354DAFFQ35200772-BE513781-9DDD-4BCA-B2C7-1E2EDCE00B44Q35221697-D39DBEA0-BD22-4A62-B1CC-227A07D91CE2Q35580390-DB254AA0-D748-4FAD-82E9-49366D08BA6AQ35826483-C68D50C7-19C8-4E5F-BDB3-099F8EEADF25Q35901659-3E8CA16C-0E48-4AE7-A080-EF162B37CCFBQ36085521-67F85A53-98EC-487A-B424-9EDA4CABCE5FQ36175170-9131D14A-50DD-4DAE-B19E-39CA4870309CQ36360311-025D3DE7-C016-48A5-9A77-0BF7E5566EA0Q36536199-4AF019E1-D45D-4CE3-AA4C-3ACE50B600EAQ36792770-7A86408D-402D-43AB-8C3F-BF2C2AF9BD6EQ37050954-A12D284D-AE3A-4F25-9521-08A081CB7747Q37119082-DCFA2D9B-8C2C-4508-AA9B-89912B9CE3CCQ37202140-93B07E55-C240-41BB-B77A-F7B4C09CBE76Q37407939-9F71DC87-41A8-4532-80AA-4620D7DEE6F3Q37408282-47BAB3B2-0E3C-4DD7-ABCF-B5FEA512D577Q37611803-E4D15F76-5508-408D-AF7C-E9FBA8D31C1FQ37712256-061B288B-41C4-4988-99EF-45EABF5BEDD7Q38076755-74FC7CD4-50D0-4C83-A6B0-9A7EF3614686Q39455827-75403F53-C94E-40F1-884A-97E2FE4D423DQ43976911-263F7560-936C-4CC9-B862-64195656DC69Q44236160-038E4729-098C-4F65-9383-7A37A9A40131Q44907869-AD947DE0-EB27-446B-8FB8-5DDDA6DD2E65Q46370506-6588A0D3-3982-4489-A222-8B4004560445Q46560092-35BD4A8A-0453-4357-82EA-956D3FCE3B77Q48615620-99CBE9D0-D6AC-4639-9650-11C7A4A57942Q51090926-51813F4B-68DE-403D-922A-38B19244F559Q58709115-42A126D0-5B0B-4734-8C1B-D38F66FB45CA
P2860
The problem of compliance to cholesterol altering therapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The problem of compliance to cholesterol altering therapy.
@en
type
label
The problem of compliance to cholesterol altering therapy.
@en
prefLabel
The problem of compliance to cholesterol altering therapy.
@en
P1476
The problem of compliance to cholesterol altering therapy.
@en
P2093
P304
P356
10.1046/J.1365-2796.1997.112133000.X
P407
P577
1997-04-01T00:00:00Z